36. 表皮水疱症 Epidermolysis bullosa Clinical trials / Disease details


臨床試験数 : 163 薬物数 : 185 - (DrugBank : 46) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 125

  
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05725018
(ClinicalTrials.gov)
March 24, 202323/1/2023EB-101 Treatment for New and Previously Treated Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)A Phase 3b Study for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) in New and Previously EB-101 Treated PatientsEpidermolysis Bullosa;Recessive Dystrophic Epidermolysis Bullosa;RDEBBiological: EB-101 Surgical application of RDEB woundsAbeona Therapeutics, IncNULLNot yet recruiting6 YearsN/AAll12Phase 3United States
2NCT05708677
(ClinicalTrials.gov)
February 9, 202123/1/2023A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEBA Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)RDEBBiological: EB-101Abeona Therapeutics, IncNULLEnrolling by invitation6 YearsN/AAll22United States
3NCT04227106
(ClinicalTrials.gov)
January 10, 202010/1/2020Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)VIITAL: A Phase 3 Study of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)Epidermolysis Bullosa;Recessive Dystrophic Epidermolysis BullosaBiological: EB-101Abeona Therapeutics, IncNULLCompleted6 YearsN/AAll11Phase 3United States
4NCT03632265
(ClinicalTrials.gov)
October 1, 201817/7/2018Study of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis BullosaVITAL: A Pivotal Phase 3 Study of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) (GENE TRANSFER)Recessive Dystrophic Epidermolysis BullosaBiological: EB-101Jean Yuh TangAbeona Therapeutics, IncNot yet recruiting6 YearsN/AAll15Phase 3NULL
5NCT03183934
(ClinicalTrials.gov)
July 20178/6/2017A Follow-up Study to Evaluate the Efficacy and Safety of ALLO-ASC-DFU in ALLO-ASC-EB-101 Clinical TrialA Follow-up Study to Evaluate the Efficacy and Safety for the Patients With ALLO-ASC-DFU Treatment in Phase 1/2 Clinical Trial of ALLO-ASC-EB-101Dystrophic Epidermolysis BullosaBiological: ALLO-ASC-DFUAnterogen Co., Ltd.NULLNot yet recruiting2 Years60 YearsAll5Phase 1/2Korea, Republic of